2.47

9.78% +0.22

After Hours: 2.47

Immix Biopharma Inc (IMMX)

Overview News Price History Financials Discussions Forecast

Immix Biopharma Inc stock is currently priced at $2.47, with a 24-hour trading volume of 96,723. It has seen a +9.78% increased in the last 24 hours and a -1.20% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.32 pivot point. If it approaches the $2.58 resistance level, significant changes may occur.

Previous Close:

$2.25

Open:

$2.35

24h Volume:

96,723

Market Cap:

$65.24M

Revenue:

Net Income/Loss:

$-14.14M

P/E Ratio:

-3.0875

EPS:

-0.8

Net Cash Flow:

$-12.64M

1W Performance:

+13.30%

1M Performance:

-1.20%

6M Performance:

-43.35%

1Y Performance:

+39.55%

1D Range:

$2.25

$2.4746

52W Range:

$1.40

$7.75

Immix Biopharma Inc Stock (IMMX) Company Profile

Name

Immix Biopharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

310 651 8041

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IMMX's Discussions on Twitter

Immix Biopharma Inc Stock (IMMX) Latest News

Private Advisor Group LLC Takes $690000 Position in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Defense World

Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Growth in Short Interest - MarketBeat

MarketBeat

Immix Biopharma, Inc. (NASDAQ:IMMX) CFO Purchases $10,035.00 in Stock - MarketBeat

MarketBeat

Immix Biopharma Inc Stock (IMMX) Financials Data

Immix Biopharma Inc (IMMX) Net Income 2024

IMMX net income (TTM) was -$14.14 million for the quarter ending September 30, 2023, a +48.00% increase year-over-year.

Immix Biopharma Inc (IMMX) Cash Flow 2024

IMMX recorded a free cash flow (TTM) of -$12.64 million for the quarter ending September 30, 2023, a -173.61% decrease year-over-year.

Immix Biopharma Inc (IMMX) Earnings per Share 2024

IMMX earnings per share (TTM) was -$0.92 for the quarter ending September 30, 2023, a +54.90% growth year-over-year.

Immix Biopharma Inc Stock (IMMX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Rachman Ilya M	CEO and Chairman	May 14 '24	Buy	2.25	4,300	9,660	912,000
Hsu Jason	Director	Dec 11 '23	Buy	4.67	31,000	144,894	813,000
Hsu Jason	Director	Dec 08 '23	Buy	4.88	25,000	122,025	782,000
Hsu Jason	Director	Sep 15 '23	Buy	2.49	7,000	17,396	757,000
Hsu Jason	Director	Sep 14 '23	Buy	2.58	10,000	25,772	750,000
Ng Carey	Director	Sep 14 '23	Buy	2.58	10,000	25,760	10,000
Hsu Jason	Director	Sep 12 '23	Buy	2.83	30,000	84,864	740,000
Adams Helen C.	Director	Sep 12 '23	Buy	2.96	13,000	38,492	13,000
Hsu Jason	Director	Sep 11 '23	Buy	2.89	25,000	72,280	710,000
Hsu Jason	Director	Sep 08 '23	Buy	2.53	10,000	25,317	685,000

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.